UltraShape (TASE: ULSP) redefines aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for fat cell destruction and body sculpting. The company develops and markets clinically proven safe and effective solutions that enhance the lives of patients. The UltraShape proprietary technology employs pulsed (non-thermal) focused ultrasound that instantly, selectively and permanently destroys fat cells without affecting surrounding structures. Founded in 2000, UltraShape has sold Contour I devices in more than 50 countries, demonstrating safety and efficacy. 

UltraShape on Tel Aviv Stock Exchange

• Only non-invasive technology scientifically validated to immediately, selectively and permanently destroy fat cells
• Clinically proven safe and effective: abdomen, flanks and thighs
• Seven peer-reviewed published articles and book chapters
• CE Mark (2005), Health Canada (2007), FDA (in-process)
• In use in more than 50 countries
• 200,000+ patient treatments worldwide
• Excellent safety profile - No reported serious adverse events
• V3 Multi-Application Pulsed Focused Ultrasound and RF platform (2010)
• Vertical Dynamic Focus™ (VDF) Pulsed Focused Ultrasound (2011)

Contact Us